Teva Sues Watson Over Application to Market Generic Cenestin

Teva Women’s Health has filed a patent-infringement suit against Watson Pharmaceuticals in response to the company’s application to make a generic version of Teva’s drug Cenestin for the treatment of menopause symptoms. Watson’s ANDA for the drug included a Paragraph IV certification indicating the company believes Teva’s ’638 patent on Cenestin (estrogens, conjugated synthetic A) is invalid and would not be infringed by the sale of a generic version of the drug, Teva says in its complaint.
Generic Line